Helix BioPharma will be presenting February 24, 2018, at the IASLC 18th Anual Targeted Therapies of Lung Cancer Meeting in Santa Monica. The Richmond Hill immuno-oncology company develops innovative drug candidates for the prevention and treatment of cancer.
Dr. George Simon an investigator at the MD Anderson Cancer Center for the Phase I study of L-DOS47 with pemetrexed and carboplatin in a first-line treatment of metastatic non-squamous non-small cell lung cancer (LDOS001) will be the speaker of this poster.
The presentation will provide an update on the progress of this clinical study, including those patients that have experienced tumor reduction or a partial response in this study.
LDOS001 is a Phase I, open label, dose escalation study being conducted in the United States at three centers; The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination. Other exploratory objectives include the evaluation of the L-DOS47 pharmacokinetics and immunogenicity.
A copy of the poster will be made available on the company’s website.